Drug Trial Radar · NCT07037771
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
70
Actual
Start
Jun 17, 2025
Primary completion
Aug 20, 2027
Study completion Aug 20, 2027
Sponsor
- Lead sponsor
- Arrowhead PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jun 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH). After completion of the double blind (DB) treatment period subjects will be eligible to continue in the optional open-label extension (OLE) period of the study. All placebo subjects who opt to continue will transition to active drug during the OLE Period.
Conditions
- Homozygous Familial Hypercholesterolemia
Interventions
zodasiran InjectionDrug
ARO-ANG3 Injection
PlaceboDrug
sterile normal saline (0.9% NaCl)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline to Month 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C) (Randomized period)Time frame: Baseline, Month 12
Locations
43 sites in 18 countries. Site status is shown where the registry gives one.
Research Site 7
Park Ridge, Illinois
Research Site 2
New York, New York
Research Site 1
Cincinnati, Ohio
Research Site 14
Pittsburgh, Pennsylvania
Research Site 13
Camperdown, New South Wales, Australia
Research Site 9
Saint Leonards, New South Wales, Australia
Research Site 21
Heidelberg, Victoria, Australia
Research Site 3
Nedlands, Western Australia, Australia
Research Site 40
Innsbruck, Austria
Research Site 39
Linz, Austria
Research Site 42
Vienna, Austria
Research Site 37
Vienna, Austria
Research Site 33
La Louvière, Belgium
Research Site 34
Leuven, Belgium
Research Site 24
Cerqueira César, São Paulo, Brazil
Research Site 4
Québec, Canada
Research Site 5
Vancouver, British Columbia, Canada
Research Site 6
Chicoutimi, Quebec, Canada
Research Site 30
Hradec Králové, Czechia
Research Site 23
Paris, France
Research Site 17
Tbilisi, Georgia
Research Site 18
Tbilisi, Georgia
Research Site 19
Tbilisi, Georgia
Research Site 35
Berlin, Germany
Research Site 10
Jerusalem, Israel
Research Site 15
Tel HaShomer, Israel
Research Site 20
Fukushima, Japan
Research Site 16
Okayama, Japan
Research Site 22
Saitama, Japan
Research Site 25
Tokyo, Japan
Research Site 26
Kanazawa, Ishikawa-ken, Japan
Research Site 27
Suita, Osaka, Japan
Research Site 12
Christchurch, New Zealand
Research Site 31
Riyadh, Saudi Arabia
Research Site 8
Cape Town, South Africa
Research Site 11
Parktown, Johannesburg, South Africa
Research Site 43
Barcelona, Spain
Research Site 28
Córdoba, Spain
Research Site 29
Madrid, Spain
Research Site 32
Gothenburg, Sweden
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.